The Patent Finder
NP

Novartis Pharma AG

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

51 patents currently held

384 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Of the 384 now held by other companies, 290 are held via Novartis AG, and 94 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
Dec 2026
Next term end
35
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists US 9,744,234
Cited by 26 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Ends May 2033 · High confidence
Also notable
Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies US 11,801,300
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2035.
Ends Dec 2035 · High confidence
Also notable
Methods of Treating Psoriasis Using IL-17 Antibody US 9,717,791
Cited by 28 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Ends May 2032 · High confidence

Formerly held, still cited

Notable
Cited by 172 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
held via Novartis AG
Ends Jan 2035 · High confidence
Also notable
Cited by 116 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Ends Oct 2032 · High confidence
Also notable
Cited by 82 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
held via Novartis AG
Ends Feb 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 30, 2027
    The maintenance fee for Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies (US 11,801,300) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
  • 1 fee due May 7, 2027
    The maintenance fee for Selection Vectors and Methods of Selecting Eukaryotic Host Cells (US 11,807,855) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
  • 3 fees due Jun 10 to 29, 2027 · next Jun 10
  • 1 fee due Jul 9, 2027
    The maintenance fee for Formulations of (S)-3-Amino-6-Methoxy-N-(3,3,3-Trifluoro-2-Hydroxy-2-Methylpropyl)-5-(TRIFLUOROMETHYL)PICOLINAMIDE (US 11,865,109) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
  • 2 fees due Sep 10 to 29, 2027 · next Sep 10
  • 1 fee due Nov 17, 2027
    The maintenance fee for Use of a Pyrazole Derivative in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (US 9,339,491) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • Oct 14Assignment recorded on 1 record: Novartis Pharma AG to Novartis AG Recorded Oct 14, 2026, executed May 7, 2015. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76662, frame 75.
  • 7 of the patents on this record were granted since Aug 23, 2026
  • 5 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,713,976Organic Compounds
In force
 · High confidence
In forceHigh confidence
US 7,713,977Organic Compounds
In force
 · High confidence
In forceHigh confidence
US 8,163,904Salts of 4-Methyl-N-[3-(4-Methyl-IMIDAZOL-1-YL)-5-Trifluoromethyl-PHENYL]-3-(4-Pyridin-3-YL-PYRIMIDIN-2-Ylamino)-BENZAMIDE
In force
 · High confidence
In forceHigh confidence
US 8,450,272Combinations of Somatostatin-Analogs with Different Selectivity for Human Somatostatin Receptor Subtypes
In force
 · High confidence
In forceHigh confidence
US 7,879,322Compositions and Methods for Use for Antibodies Against Sclerostin
In force
 · High confidence
In forceHigh confidence
US 8,246,953Compositions and Methods for Use for Antibodies Against Sclerostin
In force
 · Medium confidence
In forceMedium confidence
US 8,486,661Polynucleotides Encoding Antibodies Against Sclerostin and Uses Therefor
In force
 · Medium confidence
In forceMedium confidence
US 8,343,984Crystalline Forms of 4-Methyl-N- [3-(4-Methyl-IMIDAZOL-1-YL)-5-Trifluoromethyl-PHENYL]-3- (4-Pyridin-3-YL-PYRIMIDIN-2-Ylamino) -Benzamide
In force
 · High confidence
In forceHigh confidence
US 7,807,155IL-17 Antagonistic Antibodies
In force
 · Low confidence
In forceLow confidence
US 8,120,592Touch Sensing Substrate and Touch Sensing Liquid Crystal Display
In force
 · High confidence
In forceHigh confidence
10 of 51 patents shown.
Pro members see all 51.
Pro members: see all 51 patents
Also on record, not counted in the 51: 384 patents in force now held by others · 286 patents ended · 203 applications pending · 541 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited